Cancer Vaccines Fantasy or Future?

This publication has been discontinued on July 19, 2011.

Introduction

Executive Summary

The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way.

An example of difficulties and risks associated with this field is shown by Dendreons latest failure, in January 2005 of their late stage cancer vaccine candidate Provenge. The new and updated progress analysis report "Cancer Vaccines Fantasy or Future" by BioSeeker Group continues to provide the latest information and analysis on industry related as well as important academic activities.

Active immunotherapy strategies have emerged and progress in the molecular characterization of human tumors and a better understanding of tumor immunology has resulted in the discovery of tumor-associated antigens (TAAs). TAA-based vaccines are at present being evaluated. It is broadly admitted that therapeutic vaccines will initially and in the near future be efficient only on a limited tumor burden. Cancer vaccines ought to be used in an adjuvant setting, for instance in order to remove residual disease after surgical treatment of the tumor. As well, in light of the fact that some of these experimental vaccines can elicit immune and clinical responses even in patients with advanced cancer, cancer vaccines can also be considered for slowing down disease progression and conserve quality of life.

BioSeeker Group has since several years continuously studied the progress in cancer immunotherapy strategies. In this newly updated progress analysis we not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements.

Reasons Why You Should Read This Report:

• Get a solid background of what is happening in the Cancer Vaccine field.
• Learn how the strategies have improved.
• Make sure that you have the latest information about the most prominent Cancer Vaccine candidates.
• Speed up your R&D by finding collaborators or partners.

Table of Contents

BioSeeker Group methodology

Introduction to cancer immunotherapy

Improved strategies

Progress analysis on cancer vaccine candidates:

Allovectin-7

Avicine

BEC2

Canvaxin

CeaVac

CaPVax. (DCVax).

Gastrimmune

GMK

LymphoCide

Melacine

M-Vax

MyVax

Oncophage

OncoVAX

Osidem

Ovarex

Provenge

Theratope

TroVax

Company Profiles

Appendix: Progress profiles on therapeutic candidates

Related Reports